company background image
BXN logo

Bioxyne ASX:BXN Stock Report

Last Price

AU$0.026

Market Cap

AU$53.3m

7D

18.2%

1Y

160.0%

Updated

25 Dec, 2024

Data

Company Financials

BXN Stock Overview

A life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. More details

BXN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Bioxyne Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bioxyne
Historical stock prices
Current Share PriceAU$0.026
52 Week HighAU$0.026
52 Week LowAU$0.004
Beta0.80
1 Month Change85.71%
3 Month Change100.00%
1 Year Change160.00%
3 Year Change-10.34%
5 Year Change85.71%
Change since IPO-86.32%

Recent News & Updates

Recent updates

Shareholder Returns

BXNAU Personal ProductsAU Market
7D18.2%2.4%-1.0%
1Y160.0%31.7%7.5%

Return vs Industry: BXN exceeded the Australian Personal Products industry which returned 36.8% over the past year.

Return vs Market: BXN exceeded the Australian Market which returned 8.5% over the past year.

Price Volatility

Is BXN's price volatile compared to industry and market?
BXN volatility
BXN Average Weekly Movement22.1%
Personal Products Industry Average Movement6.0%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market3.1%

Stable Share Price: BXN's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: BXN's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1998n/aSam Watsonbioxyne.com

Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products.

Bioxyne Limited Fundamentals Summary

How do Bioxyne's earnings and revenue compare to its market cap?
BXN fundamental statistics
Market capAU$53.28m
Earnings (TTM)-AU$12.80m
Revenue (TTM)AU$9.64m

5.5x

P/S Ratio

-4.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BXN income statement (TTM)
RevenueAU$9.64m
Cost of RevenueAU$5.93m
Gross ProfitAU$3.72m
Other ExpensesAU$16.51m
Earnings-AU$12.80m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0062
Gross Margin38.53%
Net Profit Margin-132.73%
Debt/Equity Ratio1.1%

How did BXN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:35
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioxyne Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution